CorMedix Inc Aktie News

CorMedix delivered strong Q3 results, with DefenCath outperforming expectations and near-term earnings power underestimated in prior analysis. CRMD raised FY25 guidance, but long-term risks remain due to TDAPA reimbursement changes, pricing pressure, and customer concentration. The Melinta acquisition and Rezzayo prophylaxis trial offer growth optionality, but Rezzayo's success is uncertain and...

Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late 2026 5 of the 9 target profile clinical sites are now activated; completion of NEPHRO study expected i...

CorMedix Inc. ( CRMD ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Joseph Todisco - CEO & Director Elizabeth Masson-Hurlburt - Executive VP, Chief Operating Officer & Chief Integration Officer Susan Blum - EVP & Chief Financial Officer Conference Call Participants Daniel Ferry - Lifesci Advisors, LLC Leszek Sulewski - Truist Securities, Inc., Research Division Jason...

‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue Guidance Raised to a Range of $390 to $410 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J.

BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2025, before the market opens on Wednesday, November 12, 2025, and will ...

CorMedix's acquisition of Melinta Therapeutics diversifies its portfolio, boosting 2025 revenue guidance to at least $375M and reducing single-product risk. DefenCath remains the primary revenue driver, but pipeline and Melinta's hospital-focused drugs provide additional growth and risk mitigation. CorMedix is rated a Strong Buy, with a base-case fair value of $27.8, offering ~147% upside from ...

BERKELEY HEIGHTS, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that DefenCath has received an Innovative Technology designation from Vizient®, the largest healthcare performance improvement company in the country. CorMe...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of CorMedix Inc. (NASDAQ: CRMD) breached their fiduciary duties to shareholders. If you currently own CorMedix stock and acquired shares on or before October 16, 2019, you may be able to seek corporate governance reforms, the return of funds back to the company, a co...